{"id":"low-dose-erythropoietin","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Hypertension"},{"rate":"5–15","effect":"Thromboembolism (venous thromboembolism, stroke)"},{"rate":"10–20","effect":"Headache"},{"rate":"5–10","effect":"Flu-like symptoms"},{"rate":"5–10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Erythropoietin (EPO) is a cytokine that binds to the erythropoietin receptor on hematopoietic stem cells, promoting their differentiation and proliferation into mature red blood cells. At low doses, it is used to treat anemia by boosting endogenous erythropoiesis without the thromboembolic risks associated with higher doses used in cancer-related anemia.","oneSentence":"Low-dose erythropoietin stimulates erythroid progenitor cells in the bone marrow to increase red blood cell production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:11.622Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease"},{"name":"Anemia associated with chronic disease"},{"name":"Chemotherapy-induced anemia"}]},"trialDetails":[{"nctId":"NCT05949684","phase":"PHASE3","title":"ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-24","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT07422480","phase":"PHASE3","title":"A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Myelodysplastic Syndrome, Anemia","enrollment":300},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":"Prematurity, Iron-deficiency, Iron Deficiency Anemia","enrollment":120},{"nctId":"NCT05891249","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-05","conditions":"Anemia","enrollment":85},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT05617833","phase":"PHASE1","title":"Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-30","conditions":"Intraventricular Hemorrhage of Prematurity","enrollment":60},{"nctId":"NCT06854276","phase":"PHASE2","title":"Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-03-01","conditions":"Chemotherapy-induced Anemia, Non-myeloid Malignancies","enrollment":80},{"nctId":"NCT04707768","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2021-06-18","conditions":"Anemia Associated With Chronic Kidney Disease (CKD)","enrollment":456},{"nctId":"NCT03682536","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-01-02","conditions":"Myelodysplastic Syndromes","enrollment":363},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":"Renal Anemia Associated With Chronic Renal Failure (CRF)","enrollment":130},{"nctId":"NCT03263091","phase":"PHASE3","title":"Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden","status":"TERMINATED","sponsor":"Kyntra Bio","startDate":"2018-01-29","conditions":"Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia","enrollment":184},{"nctId":"NCT01471015","phase":"PHASE1, PHASE2","title":"Darbe Administration in Newborns Undergoing Cooling for Encephalopathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2012-09","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":30},{"nctId":"NCT05395195","phase":"PHASE3","title":"Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-12-31","conditions":"Encephalopathy, Erythropoietin, Newborn Asphyxia","enrollment":504},{"nctId":"NCT04330729","phase":"NA","title":"The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp","status":"RECRUITING","sponsor":"Zealand University Hospital","startDate":"2020-04-15","conditions":"Erythropoietin Adverse Reaction","enrollment":60},{"nctId":"NCT05907499","phase":"PHASE3","title":"Decitabine for Poor Graft Function Post Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-07-01","conditions":"Poor Graft Function","enrollment":76},{"nctId":"NCT04885647","phase":"PHASE2","title":"A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2021-03-12","conditions":"Renal Anemia of Chronic Kidney Disease","enrollment":60},{"nctId":"NCT05629598","phase":"PHASE2","title":"A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2022-04-13","conditions":"Renal Anemia","enrollment":150},{"nctId":"NCT01244763","phase":"PHASE2","title":"Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-10-29","conditions":"Chronic Kidney Disease, Anemia","enrollment":145},{"nctId":"NCT01147666","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-05-17","conditions":"End Stage Renal Disease, Anemia","enrollment":161},{"nctId":"NCT02052310","phase":"PHASE3","title":"Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2014-02-11","conditions":"Anemia in Incident Dialysis Patients","enrollment":1043},{"nctId":"NCT03277183","phase":"PHASE4","title":"Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2017-11-02","conditions":"Anemia, CKD, Atherosclerosis","enrollment":5},{"nctId":"NCT02145026","phase":"PHASE4","title":"A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-06","conditions":"Myelodysplastic Syndromes","enrollment":100},{"nctId":"NCT00071799","phase":"PHASE3","title":"A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-11-01","conditions":"Myelodysplastic Syndromes","enrollment":358},{"nctId":"NCT03835507","phase":"PHASE1, PHASE2","title":"Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2016-06-20","conditions":"Amyotrophic Lateral Sclerosis","enrollment":64},{"nctId":"NCT01817699","phase":"PHASE4","title":"Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"CANDLE-KIT Trial Study Group","startDate":"2013-04","conditions":"Kidney Transplantation, Anemia, Vitamin D Deficiency","enrollment":161},{"nctId":"NCT02175277","phase":"PHASE3","title":"Darbepoetin Alfa MDS Companion Protocol","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06-12","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":9},{"nctId":"NCT01868477","phase":"PHASE2","title":"Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-28","conditions":"Low and Int 1-risk Myelodysplastic Syndrome","enrollment":28},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT01581073","phase":"PHASE3","title":"PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2012-02-16","conditions":"Chronic Kidney Disease, Diabetes","enrollment":476},{"nctId":"NCT00379912","phase":"PHASE2","title":"Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Larry Cripe, MD","startDate":"2006-09","conditions":"Myelodysplastic Syndromes","enrollment":15},{"nctId":"NCT01034657","phase":"PHASE2","title":"LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":34},{"nctId":"NCT00017004","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-08","conditions":"Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma","enrollment":114},{"nctId":"NCT00642668","phase":"PHASE4","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06-30","conditions":"Anemia","enrollment":35},{"nctId":"NCT02260414","phase":"PHASE2","title":"Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-04-14","conditions":"Lymphoma, Multiple Myeloma","enrollment":19},{"nctId":"NCT03093506","phase":"EARLY_PHASE1","title":"Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2011-09","conditions":"Human Volunteers","enrollment":25},{"nctId":"NCT01555515","phase":"PHASE1, PHASE2","title":"Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant","status":"TERMINATED","sponsor":"Medgenics Medical Israel Ltd.","startDate":"2012-03","conditions":"Anemia, End Stage Renal Disease","enrollment":4},{"nctId":"NCT00551291","phase":"PHASE2","title":"A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT00827021","phase":"PHASE3","title":"The Clinical Evaluation of the Dose of Erythropoietins Trial","status":"COMPLETED","sponsor":"Giovanni FM Strippoli, MD","startDate":"2009-07","conditions":"Kidney Failure, Chronic","enrollment":656},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT01497145","phase":"PHASE2","title":"A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-12","conditions":"MDS","enrollment":45},{"nctId":"NCT00440466","phase":"PHASE3","title":"PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-07","conditions":"Anemia, Renal Diseases","enrollment":430},{"nctId":"NCT00542568","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Sustained Erythropoietin Therapy","status":"COMPLETED","sponsor":"Medgenics Medical Israel Ltd.","startDate":"2008-08","conditions":"Anemia","enrollment":19},{"nctId":"NCT01584921","phase":"PHASE1","title":"Renal Effects of Erythropoietin in Humans","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2012-03","conditions":"Renal Effects","enrollment":16},{"nctId":"NCT00910858","phase":"PHASE1, PHASE2","title":"A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2005-01","conditions":"Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)","enrollment":40},{"nctId":"NCT00589953","phase":"PHASE2","title":"High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study","status":"TERMINATED","sponsor":"Atlantic Health System","startDate":"2007-07","conditions":"Infant, Premature, Erythropoietin, Brain Injury","enrollment":22},{"nctId":"NCT00695396","phase":"PHASE3","title":"A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-06","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":25},{"nctId":"NCT00938314","phase":"PHASE2","title":"Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","status":"TERMINATED","sponsor":"Stem Cell Therapeutics Corp.","startDate":"2009-08","conditions":"Stroke","enrollment":96},{"nctId":"NCT00804050","phase":"PHASE3","title":"Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts","status":"TERMINATED","sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","startDate":"2007-03","conditions":"Myelodysplastic Syndromes","enrollment":184},{"nctId":"NCT00495365","phase":"PHASE4","title":"A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.","status":"TERMINATED","sponsor":"Ortho Biotech Products, L.P.","startDate":"2003-06","conditions":"Anemia, Chronic Renal Insufficiency","enrollment":8},{"nctId":"NCT00270114","phase":"PHASE2, PHASE3","title":"A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Anemia, Blood Transfusion, Orthopedic Procedures","enrollment":55},{"nctId":"NCT00568542","phase":"PHASE4","title":"Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-05","conditions":"Ischemic Cardiomyopathy","enrollment":28},{"nctId":"NCT00910234","phase":"PHASE1, PHASE2","title":"Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2009-08","conditions":"Infant, Premature, Leukomalacia, Periventricular, Intraventricular Hemorrhage","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low dose"],"phase":"marketed","status":"active","brandName":"Low dose erythropoietin","genericName":"Low dose erythropoietin","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose erythropoietin stimulates erythroid progenitor cells in the bone marrow to increase red blood cell production. Used for Anemia of chronic kidney disease, Anemia associated with chronic disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}